Article Correctness Is Author's Responsibility: Levels of sBTLA proteins as potential marker of overall survival of liver cancer patients

(Osaka City University) Researchers at Osaka City University Graduate School of Medicine introduced sorafenib to patients with advanced stages of the liver cancer hepatocellular carcinoma (HCC) and measured the amount of 16 circulating soluble immune checkpoint proteins. Their data suggest that a high amount of sBTLA proteins may be a marker of overall survival in patients with HCC.